ChroMedX Corp. Awarded Two New Patents on Ultra-Filtration Technology
Toronto, Ontario--(Newsfile Corp. - September 30, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that the Company has been awarded two additional Canadian patents on its Automated Ultra Filtration (AUF) technology. These patents demonstrate the novelty, inventiveness and usefulness of the AUF technology, and are listed below: 1. CA No. 2,876,445 entitled "AUTOMATED...
2015-09-30 4:07 PM EDT
ChroMedX Callaborates with Biointerfaces Institute and Receives Grant
Toronto, Ontario--(Newsfile Corp. - September 16, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that it has entered into a collaboration with Dr. Leyla Soleymani of the Biointerfaces Institute of McMaster University and received an Engage Grant from NSERC (Natural Sciences and Engineering Research Council of Canada) to further HemoPalmTM biosensor development. Dr....
2015-09-16 4:07 PM EDT
ChroMedx Reports Testing of Key HemoPalm Analyzer Component
Toronto, Ontario--(Newsfile Corp. - September 8, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report that testing has commenced on the key spectroscopic component of the Analyzer of HemoPalmTM blood analysis device. The spectroscopic analysis of blood samples is a key aspect of the HemoPalm system which significantly differentiates it from other point-of-care blood analyzers and...
2015-09-08 4:25 PM EDT
ChroMedX Announces Completion of HemoPalm(TM) Prototype Cartridge
Toronto, Ontario--(Newsfile Corp. - September 4, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report the completion of the HemoPalm™ System Prototype Cartridge. In conjunction with the previously announced ENGAGE grant with McMaster University's Manufacturing Research Institute (MMRI), the Company has completed the fabrication of the prototype HemoPalm™ cartridge, a key...
2015-09-04 4:30 PM EDT
ChroMedX Engages Polygenesis Corporation for Completion of HemoPalm(TM) Alpha
Toronto, Ontario--(Newsfile Corp. - September 2, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce the engagement of technology development and prototyping firm Polygenesis Corporation to continue the development of the HemoPalm™ biosensor array, a fundamental component of the HemoPalm™ system. Polygenesis will build on the initial work carried out by Aline Inc. and complete...
2015-09-02 4:30 PM EDT
ChroMedX Submits PCT Patent Application for HemoPalm(TM) Blood Analysis System
Toronto, Ontario--(Newsfile Corp. - August 28, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) technologies is pleased to announce the filing of a PCT (Patent Cooperation Treaty) Patent Application pertaining to the HemoPalm™ Cartridge and Analyzer system called "Joint Spectroscopic and Biosensor System for Point-of-Care Testing" (PCT/CA2015/050455). PCT/CA2015/050455 has the potential to...
2015-08-28 4:30 PM EDT
ChroMedX Corp. Announces OTCQB Listing
Toronto, Ontario--(Newsfile Corp. - August 4, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that its common shares recently commenced trading on the OTCQB®, under the symbol "MNLIF". Real-time quotes and market information on the Company are available at http://www.otcmarkets.com/stock/MNLIF/quote "We are very pleased to be listed on the OTCQB and to have our shares...
2015-08-04 2:02 PM EDT
ChroMedX Corp. Closes Private Placement of Units
Toronto, Ontario--(Newsfile Corp. - July 10, 2015) - ChroMedX Corp. (CSE: CHX) (the "Company") is pleased to announce that it has completed its previously announced non-brokered private placement (the "Offering") for gross proceeds of CDN[$1,148,681.50] through the issuance of [9,189,452] units (each a "Unit") at a price of CDN$0.125 per Unit. Each Unit is comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"), each Warrant...
2015-07-10 4:10 PM EDT
ChroMedX Announces Private Placement of Units
Toronto, Ontario--(Newsfile Corp. - July 7, 2015) - ChroMedX Corp. (CSE: CHX) (the "Company" or "ChroMedX") would like to announce that it intends to complete a non-brokered private placement (the "Offering") for gross proceeds of up to CDN$1,200,000 through the issuance of up to 9,600,000 units (each a "Unit") at a price of CDN$0.125 per Unit. Each Unit will be comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"), each Warrant...
2015-07-07 4:15 PM EDT
ChroMedX Welcomes Dr. Nick Smit to Biosensor Development Team
Toronto, Ontario--(Newsfile Corp. - March 25, 2015) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of Dr. Nick Smit as part of the HemoPalm biosensor development team. Dr. Nick Smit received his Ph.D. in Analytical Chemistry from the University of Delaware and began his career at i-Stat in Princeton, New Jersey and later Ottawa, Ontario where he rose to the...
2015-03-25 4:49 PM EDT
ChroMedX Appoints Dr. Robert Smyth to Technical Advisory Board
Toronto, Ontario--(Newsfile Corp. - March 24, 2015) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the appointment of anesthesiologist Dr. Robert Smyth to the Company's Technical Advisory Board. Dr. Smyth completed his MD from the University of Calgary and his anesthesia residency at the University of Toronto. He is an anesthesiologist at Southlake Regional Health Centre in...
2015-03-24 4:16 PM EDT
ChroMedX Collaborates with Microfluidic and Microfabrication Experts for HemoPalm Cartridge Development
Toronto, Ontario--(Newsfile Corp. - March 23, 2015) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce it has entered into a collaboration with Dr. Ravi Selvaganapathy of McMaster University to assist in the design and development of prototype cartridges for the Company's patented HemoPalm blood analyzer system. The McMaster and ChroMedX partnership has been awarded an NSERC Engage...
2015-03-23 4:30 PM EDT
ChroMedX Submits US Provisional Patent Application for Recently Developed Aspects of HemoPalm Blood Analysis System
Toronto, Ontario--(Newsfile Corp. - March 10, 2015) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) technologies is pleased to announce the filing of a second US Provisional Patent Application pertaining to the HemoPalm Cartridge and Analyzer system. The second US Provisional Patent Application No. 62/114,700 entitled "Joint Spectroscopic and Biosensor System for Point-of-Care Testing" was filed...
2015-03-10 3:30 PM EDT
ChroMedX Engages Biosensor Development Expert Stephen Cozzette
Toronto, Ontario--(Newsfile Corp. - January 26, 2015) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of Mr. Stephen Cozzette as a consultant on the HemoPalm project focussing on the electrochemical sensor and cartridge development aspects of the project. "We are very excited to add Stephens's expertise to the team. Mr. Cozzette is particularly skilful at...
2015-01-26 5:00 PM EST
ChroMedX Exhibits and Presents at Cantech ’15 in Toronto, Canada
Toronto, Ontario--(Newsfile Corp. - January 13, 2015) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that the Company will be presenting and exhibiting at the Cantech '15 Technology Conference on Thursday, January 15, 2015 in Toronto, Ontario Canada. ChroMedX President and CEO, Dr. Wayne Maddever, will be conducting a feature presentation covering the Company's technologies...
2015-01-13 3:24 PM EST
ChroMedX 2014 Progress Update
Toronto, Ontario--(Newsfile Corp. - December 19, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is proud to report on the Company's corporate and developmental progress in 2014. ChroMedX listed in mid-July 2014 and has made significant progress in the development of its patented technologies as well as advancement of the Corporation as a public entity. "We are very pleased with the progress...
2014-12-19 4:15 PM EST
Chromedx Completes Acquisition of Automated Ultrafiltration Immunoassay Technology
Toronto, Ontario--(Newsfile Corp. - December 15, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the it has closed its previously announced acquisition of patent application PCT/CA2013/050935 related to Automated Ultrafiltration Technology and associated intellectual property ("AUF") from InvidX Corp., pursuant to an option agreement dated June 16, 2014 (the "Option...
2014-12-15 6:30 AM EST
ChroMedX Commences AUF Development with Aline Inc. and Spectrum Labs
Toronto, Ontario--(Newsfile Corp. - December 9, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of ALine Inc. as primary contractor for the development of its recently acquired Automated Ultrafiltration (AUF) Cartridge. The AUF cartridge will be used as part of an automated system in the preparation of plasma/serum samples for immunoassay or mass...
2014-12-09 4:30 PM EST
ChroMedX Acquires Automated Ultrafiltration Immunoassay Technology
Toronto, Ontario--(Newsfile Corp. - November 28, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the acquisition of the Automated Ultrafiltration Technology "AUF" and associated intellectual property. "After thorough investigation of the technology, potential market, and development requirements we are very enthused to add the AUF technology to our portfolio. We found...
2014-11-28 3:53 PM EST
ChroMedX Announces Biosensor Development and HemoPalm Update
Toronto, Ontario--(Newsfile Corp. - November 24, 2014) - ChroMedX Corp. (the “Company”) (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care technologies is pleased to provide an update on the Company’s HemoPalm handheld analyser/Cartridge technology and the commencement of biosensor development. Lead contractor, Aline Inc. has taken delivery of the first batch of biosensors in Rancho Dominguez, CA. and the initial test programme has commenced. The...
2014-11-24 3:30 AM EST